Dr. Mahantshetty Discusses Results of Chemoradiation in Cervical Cancer

Umesh Mahantshetty, MD, MBBS
Published: Tuesday, Nov 07, 2017



Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

In a trial of patients with stage IIIB squamous cell carcinoma of the uterine cervix, cisplatin chemoradiation and radiation were compared. The aim was to see whether chemoradiation was beneficial in this population.

An absolute benefit of 8% and 8.5% for disease-free survival and overall survival was observed in the chemoradiation arm.
 


Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

In a trial of patients with stage IIIB squamous cell carcinoma of the uterine cervix, cisplatin chemoradiation and radiation were compared. The aim was to see whether chemoradiation was beneficial in this population.

An absolute benefit of 8% and 8.5% for disease-free survival and overall survival was observed in the chemoradiation arm.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x